Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs

Abstract

Exposure of human tumor cell lines to moderate doses of anticancer agents induces terminal proliferation arrest accompanied by morphologic and enzymatic changes that resemble senescence of normal cells. We have investigated the role of p53 and p21waf1/cip1 in the induction of this response in drug-treated tumor cells. Doxorubicin treatment induced the senescence-like phenotype (SLP) and its associated terminal growth arrest in wild-type HCT116 colon carcinoma cells; this response was strongly decreased but not abolished in HCT116 lines with homozygous knockout of p53 or p21. Transduction of HT1080 fibrosarcoma cells with a genetic inhibitor of p53 also decreased the induction of SLP and increased drug-induced mitotic cell death. To determine if drug-stimulated p21 expression was responsible for senescence-like growth arrest, we have expressed different levels of p21 from an inducible promoter. While high-level overexpression of p21 was sufficient to induce SLP in HT1080 cells, the levels of p21 expressed in doxorubicin-treated cells could account for only a fraction of doxorubicin-induced SLP. Our results indicate that p53 and p21 act as positive regulators of senescence-like terminal proliferation arrest, but their function is neither sufficient nor absolutely required for this treatment response in tumor cells.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Volgelstein B. . 1998 Science 282: 1497–1501.

  • Campisi J. . 1997 Eur. J. Cancer 33: 703–709.

  • Chang B-D and Roninson IB. . 1996 Gene 183: 137–142.

  • Chang B-D, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K and Roninson IB. . 1999 Cancer Res. 59: 3761–3767.

  • Chen Q and Ames BN. . 1994 Proc. Natl. Acad. Sci. USA 91: 4130–4134.

  • Duncan EL and Reddel RR. . 1997 Biochemistry (Mosc) 62: 1263–1274.

  • DiLeonardo A, Linke SP, Clarkin K and Wahl GM. . 1994 Genes Dev. 8: 2540–2551.

  • Dimri GP, Xinhua L, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubej I, Pereira-Smith O, Peacocke M and Campisi J. . 1995 Proc. Natl. Acad. Sci. USA 92: 9363–9367.

  • el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. . 1993 Cell 75: 817–825.

  • Harper JW, Adami G, Wei N, Keyomarsi K and Elledge S. . 1993 Cell 75: 805–816.

  • Hayflick L and Moorhead PS. . 1961 Exp. Cell Res. 37: 585–621.

  • Hendry JH and West CML. . 1997 Int. J. Radiat. Biol. 71: 709–719.

  • Holt SE, Aisner DL, Shay JW and Wright WE. . 1997 Proc. Natl. Acad. Sci. USA 94: 10687–10692.

  • Horan PK and Slezak SE. . 1989 Nature 340: 167–168.

  • Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L. . 1996 Cancer Res. 56: 816–825.

  • Kandel ES, Chang BD, Schott B, Shtil AA, Gudkov AV and Roninson IB. . 1997 Somatic Cell Mol. Genet. 23: 325–340.

  • Liu LF. . 1989 Annu. Rev. Biochem. 58: 351–375.

  • Lock RB and Stribinskiene L. . 1996 Cancer Res. 56: 4006–4012.

  • Lowe SW, Ruley HE, Jacks T and Housman DE. . 1993 Cell 74: 957–968.

  • Miller DA and Rosman GJ. . 1989 Biotechniques 7: 980–986.

  • Myohanen SK, Baylin SB and Herman JG. . 1998 Cancer Res. 58: 591–593.

  • Ossovskaya VS, Mazo IA, Chernov MV, Chernova OB, Strezoska Z, Kondratov R, Stark GR, Chumakov PM and Gudkov AV. . 1996 Proc. Natl. Acad. Sci. USA 93: 10309–10314.

  • Pear WS, Nolan GP, Scott ML and Baltimore D. . 1993 Proc. Natl. Acad. Sci. USA 90: 8392–8396.

  • Pellegata NS, Antoniono RJ, Redpath JL and Stanbridge EJ. . 1996 Proc. Natl. Acad. Sci. USA 93: 15209–15214.

  • Pereira-Smith OM and Smith JR. . 1988 Proc. Natl. Acad. Sci. USA 85: 6042–6046.

  • Perry ME, Rolfe M, McIntyre P, Commane M and Stark GR. . 1992 Mutat. Res. 276: 189–197.

  • Robles SJ and Adami GR. . 1998 Oncogene 16: 1113–1123.

  • Schott B, Iraj ES and Roninson IB. . 1996 Somatic Cell Mol. Genet. 22: 292–309.

  • Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW. . 1997 Cell 88: 593–602.

  • Shay JW. . 1997 J. Cell Physiol. 173: 266–270.

  • Sugrue MM, Shin DY, Lee SW and Aaronson SA. . 1997 Proc. Natl. Acad. Sci. USA 94: 9648–9653.

  • Torres K and Horwitz SB. . 1998 Cancer Res. 58: 3620–3626.

  • Uhrbom L, Nister M and Westermark B. . 1997 Oncogene 15: 505–514.

  • Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T and Haas M. . 1998 Cell. Growth Differ. 9: 139–146.

  • Waldman T, Kinzler KW and Vogelstein B. . 1995 Cancer Res. 55: 5187–5190.

  • Waldman T, Lengauer C, Kinzler KW and Vogelstein B. . 1996 Nature 381: 713–716.

  • Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B and Williams J. . 1997 Nature Medicine 3: 1034–1036.

  • Wang X, Wong SC, Pan J, Tsao SW, Fung KH, Kwong DL, Sham JS and Nicholls JM. . 1998a Cancer Res. 58: 5019–5022.

  • Wang Y, Blandino G, Oren M and Givol D. . 1998b Oncogene 17: 1923–1930.

  • Weinberg RA. . 1997 Cell 88: 573–575.

  • Whitaker NJ, Bryan TM, Bonnefin P, Chang A C-M, Musgrove EA, Breithwaite AW and Reddel RR. . 1995 Oncogene 11: 971–976.

  • Xu H-J, Zhou Y, Ji W, Perng G-S, Kruzelock R, Kong C-T, Bast RC, Mills GB, Li J and Hu S-X. . 1997 Oncogene 15: 2589–2596.

  • Zhu J, Woods D, McMahon M and Bishop JM. . 1998 Genes Dev. 12: 2997–3007.

Download references

Acknowledgements

We thank Dr B Vogelstein for the wild-type, p21−/− and p53−/− HCT116 cell lines, Dr AV Gudkov for the L56SN vector, Dr ES Kandel for constructing the Lm56SE vector, and Dr K Hagen for assistance with flow sorting. This work was supported by grants R01CA62099 and R37CA40333 from the National Cancer Institute.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, BD., Xuan, Y., Broude, E. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808–4818 (1999). https://doi.org/10.1038/sj.onc.1203078

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203078

Keywords

Search

Quick links